恒瑞医药：HRS-4642注射液纳入突破性治疗品种名单

Core Viewpoint - Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapies by the National Medical Products Administration, targeting first-line treatment for advanced or metastatic pancreatic cancer with KRAS G12D mutation [1] Group 1: Product Development - HRS-4642 is a liposomal formulation KRAS G12D inhibitor that specifically binds to KRAS G12D, inhibiting the phosphorylation of MEK and ERK proteins to exert anti-tumor effects [1] - The total R&D investment for the related project has reached approximately 254 million yuan [1] Group 2: Regulatory and Market Context - The inclusion in the breakthrough therapy list indicates potential expedited development and approval processes, which may enhance market opportunities for the product [1] - Drug development is subject to various uncertainties related to technology, approval, and policy factors [1]